Saama Named to 50 Best Companies to Watch 2022

Bringing Treatments to Patients Faster by Democratizing ClinTech

The Silicon Review talked with Suresh Katta, Saama’s Chairman Emeritus, about using artificial intelligence (AI) and other innovative technologies to reimagine the drug development paradigm.
The wide-ranging interview touched on how disruptive technologies can enhance the development of treatments for rare diseases, bridge gaps created by The Great Resignation, and help pharma and biotech companies achieve scale, acceleration, and repeatability across therapeutic areas.

Read the Article